Theravance Biopharma’s (TBPH) Buy Rating Reiterated at BTIG Research

BTIG Research reissued their buy rating on shares of Theravance Biopharma (NASDAQ:TBPH) in a report released on Tuesday,Benzinga reports. BTIG Research currently has a $40.00 target price on the biopharmaceutical company’s stock.

Several other equities research analysts also recently weighed in on TBPH. Wall Street Zen downgraded shares of Theravance Biopharma from a “strong-buy” rating to a “buy” rating in a report on Saturday, January 3rd. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Theravance Biopharma in a research note on Thursday, January 22nd. HC Wainwright raised their price objective on shares of Theravance Biopharma from $15.00 to $20.00 and gave the company a “buy” rating in a research note on Tuesday, November 11th. Finally, Oppenheimer started coverage on Theravance Biopharma in a report on Wednesday, December 3rd. They set an “outperform” rating and a $27.00 target price on the stock. Two equities research analysts have rated the stock with a Strong Buy rating, three have given a Buy rating and two have issued a Hold rating to the stock. According to MarketBeat, Theravance Biopharma has a consensus rating of “Buy” and an average target price of $27.80.

Theravance Biopharma Trading Down 2.5%

NASDAQ TBPH opened at $19.58 on Tuesday. The company has a 50-day moving average price of $19.07 and a two-hundred day moving average price of $15.87. Theravance Biopharma has a 52 week low of $7.90 and a 52 week high of $21.03. The stock has a market cap of $992.12 million, a price-to-earnings ratio of 34.35 and a beta of 0.15.

Theravance Biopharma (NASDAQ:TBPH) last issued its quarterly earnings data on Monday, November 10th. The biopharmaceutical company reported $0.07 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.03) by $0.10. The business had revenue of $19.99 million during the quarter, compared to analyst estimates of $19.89 million. Theravance Biopharma had a return on equity of 12.20% and a net margin of 36.53%. As a group, equities research analysts expect that Theravance Biopharma will post -1.09 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Theravance Biopharma news, SVP Rhonda Farnum sold 31,067 shares of Theravance Biopharma stock in a transaction that occurred on Wednesday, December 3rd. The shares were sold at an average price of $18.75, for a total value of $582,506.25. Following the transaction, the senior vice president owned 277,695 shares in the company, valued at approximately $5,206,781.25. The trade was a 10.06% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. 6.90% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Theravance Biopharma

Large investors have recently modified their holdings of the stock. Arrowstreet Capital Limited Partnership acquired a new stake in shares of Theravance Biopharma during the third quarter worth $10,611,000. Assenagon Asset Management S.A. increased its stake in Theravance Biopharma by 1,629.4% in the 3rd quarter. Assenagon Asset Management S.A. now owns 414,715 shares of the biopharmaceutical company’s stock worth $6,055,000 after purchasing an additional 390,735 shares in the last quarter. Hillsdale Investment Management Inc. acquired a new stake in Theravance Biopharma during the 3rd quarter worth about $4,536,000. Jefferies Financial Group Inc. lifted its stake in Theravance Biopharma by 1,191.9% during the second quarter. Jefferies Financial Group Inc. now owns 276,887 shares of the biopharmaceutical company’s stock valued at $3,054,000 after buying an additional 255,455 shares in the last quarter. Finally, Two Sigma Investments LP boosted its holdings in shares of Theravance Biopharma by 1,199.9% in the third quarter. Two Sigma Investments LP now owns 231,272 shares of the biopharmaceutical company’s stock worth $3,377,000 after buying an additional 213,480 shares during the period. 99.10% of the stock is owned by institutional investors.

Theravance Biopharma Company Profile

Theravance Biopharma is a biopharmaceutical company focused on the discovery, development and commercialization of innovative medicines, primarily in the areas of respiratory disease, inflammatory and immunology, and rare disorders. The company develops small-molecule therapies designed to address unmet medical needs by targeting specific molecular pathways. Its lead marketed product, YUPELRI® (revefenacin) inhalation solution, is the first and only once-daily, long-acting muscarinic antagonist (LAMA) approved by the U.S.